249 related articles for article (PubMed ID: 17138818)
1. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
7. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
8. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
9. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
10. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
Ho VT; Kim HT; Aldridge J; Liney D; Kao G; Armand P; Koreth J; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1196-204. PubMed ID: 21193054
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
Parta M; Shah NN; Baird K; Rafei H; Calvo KR; Hughes T; Cole K; Kenyon M; Schuver BB; Cuellar-Rodriguez J; Zerbe CS; Holland SM; Hickstein DD
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1250-1259. PubMed ID: 29412158
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
16. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
17. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
18. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
[TBL] [Abstract][Full Text] [Related]
19. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
